Health & coverage · Prostate cancer
Prostate cancer is one of the most survivable cancers — and one of the most misunderstood when it comes to life insurance. Three things decide your options: how long since treatment ended, whether you’re still on hormone therapy like Lupron or Casodex, and whether you’re being watched rather than treated. Here’s the honest map.
The honest landscape
Once treatment is behind you, the published clocks are reasonable. Transamerica’s FE Express guide gives prostate cancer its own row: under two years since last treatment is a decline, two to five years reaches its Select class, and five or more its best Premier class (Premier isn’t offered in California). Corebridge’s SimpliNow Legacy guide lists Stage 1 prostate cancer diagnosed or treated within the last 48 months for its level plan, and Stage II within 48 months for graded. The general cancer clocks fill in the rest: United Home Life reaches Premier at two years cancer-free, Mutual of Omaha’s Living Promise grades two to four years out and goes Level after four (per FMO-published grids), and Royal Neighbors grades two to five years and offers Standard after five.
Hormone therapy is where carriers part ways most sharply. Transamerica’s FE Express drug list names Lupron, Eligard, Casodex (bicalutamide), Zytiga, Xtandi, Erleada, Nubeqa, and Orgovyx — current use means no FE Express coverage at all. Mutual of Omaha lists Casodex, Eligard, and Zoladex as not eligible for Living Promise, Level or Graded. Aetna’s published drug list marks Lupron, Eligard, Casodex, Zoladex, Zytiga, and Xtandi unacceptable on all three Accendo plans. American Amicable’s Senior Choice is the exception: it rates Lupron and Casodex by fill date — return-of-premium plan within two years, Graded within three, Immediate after that.
Active surveillance is its own situation, because being watched isn’t the same as being finished. United Home Life’s guide routes cancer with no treatment or under watchful waiting to its conditionally guaranteed plan, and American Amicable’s Senior Choice treats a current cancer as not eligible; most published clocks count from the end of treatment, so surveillance is a conversation to have with us before you apply anywhere. It’s also exactly what guaranteed-issue whole life is for: it asks nothing. Mutual of Omaha’s runs to age 85, Corebridge’s and Americo’s to 80 — with a graded period for natural-cause death in the first two years (three at Americo) and full accidental coverage from day one.
Your realistic paths
Transamerica FE Express Select at 2–5 years and Premier at 5+; United Home Life Premier at 2 years cancer-free; Mutual of Omaha Level after 4; Royal Neighbors Standard after 5. Corebridge lists Stage 1 within 48 months for its level plan.
Mutual of Omaha (2–4 years), Royal Neighbors (2–5 years), United Home Life (12–24 months cancer-free), and American Amicable, which rates Lupron and Casodex by fill date instead of excluding them.
No health questions — hormone therapy, radiation, watchful waiting, anything. Mutual of Omaha to 85, Corebridge and Americo to 80. Graded period for natural causes; accidents covered in full from day one.
What moves the needle
Current Lupron, Eligard, Casodex, Zytiga, or Xtandi rules out Transamerica’s FE Express and Aetna’s Accendo plans outright; American Amicable instead rates Lupron and Casodex by how recently they were filled.
Two years after last treatment is the first big door — Transamerica FE Express Select, United Home Life Premier. Five years opens Transamerica’s Premier class and Royal Neighbors’ Standard tier.
Corebridge separates Stage 1 (level plan) from Stage II (graded) within 48 months; Transamerica declines any spread to lymph nodes or other organs, a recurrence, or cancer at multiple sites.
Inside the application
Where the doors are
Every carrier draws its lines differently — these documented niches are why we shop your exact situation instead of accepting the first answer. Sources labeled; guidelines change without notice.
FE Express: Select 2–5 years after last treatment, Premier at 5+, when treatment is complete with no spread or recurrence. Current Lupron, Eligard, Casodex, Zytiga, Xtandi, Erleada, Nubeqa, or Orgovyx means no FE Express coverage.
Our full Transamerica reviewThe SimpliNow Legacy training guide lists Stage 1 prostate cancer diagnosed or treated within the last 48 months for its level plan, and Stage II within 48 months for graded (ages 50–80). It’s a 2021 guide — we confirm current rules before quoting.
Our full AIG (Corebridge) reviewSenior Choice rates Lupron and Casodex by fill date rather than excluding them: within 2 years routes to the return-of-premium plan, within 3 to Graded, older to Immediate. A current cancer is not eligible for any plan.
Our full American Amicable reviewCasodex, Eligard, and Zoladex are on Living Promise’s not-eligible drug list — current use rules out both the Level and Graded plans. Off those drugs, your cancer timeline decides between Graded and Level.
Our full Mutual of Omaha reviewThe only guide we reviewed that names watchful waiting: untreated cancer routes to its conditionally guaranteed plan. Cancer-free 12–24 months routes to its graded Express Issue plan; 2+ years reaches Premier, and 5+ years opens term too.
Its published drug list (2020 edition) marks Lupron, Eligard, Casodex, Zoladex, Zytiga, and Xtandi unacceptable on all three Accendo plans. If you’re still on hormone therapy, we look elsewhere first.
Our full Aetna (Accendo) reviewStraight answers
Yes, though fewer doors are open. Current use rules out Transamerica’s FE Express, Aetna’s Accendo plans, and — for Casodex, Eligard, or Zoladex — Mutual of Omaha’s Living Promise. American Amicable’s Senior Choice rates Lupron and Casodex by fill date instead, routing recent use to its return-of-premium or Graded plans. And guaranteed-issue whole life asks no questions at all: ages 45–85 with Mutual of Omaha, with a graded period for natural causes and accidents covered in full from day one.
Honestly, fewer than after treatment. United Home Life routes watchful waiting to its conditionally guaranteed plan, American Amicable’s Senior Choice treats a current cancer as not eligible, and most published clocks count from the end of treatment. Guaranteed-issue whole life — no health questions, Mutual of Omaha to 85, Corebridge and Americo to 80 — is the dependable route. If you later complete treatment, the day-one ladder typically opens two to five years after.
Pending tests are their own question. NewBridge treats a recommended diagnostic test you haven’t completed (routine screening excluded) as not eligible, Transamerica FE Express declines pending tests or results, Royal Neighbors routes pending evaluation to guaranteed issue only, and American Amicable’s Senior Choice routes it to its return-of-premium plan — so it’s usually better to get your results first. And an enlarged prostate isn’t cancer: American Amicable’s term guide lists benign prostatic hypertrophy with a stable PSA at Standard.
Usually two to five years from your last treatment: Transamerica FE Express Select and United Home Life Premier at two years, Mutual of Omaha Level at four, Transamerica Premier and Royal Neighbors Standard at five. Corebridge’s guide is the outlier, listing Stage 1 prostate cancer within the last 48 months for its level plan. Ongoing hormone therapy can change the answer, so bring your medication list.
One search, every door
A few basic questions — age, state, and your honest health picture — are exactly what lets us quote you accurately across the whole panel. A decline somewhere else is the start of our search, not the end. No exam to look, no spam, no pressure.
